The bacterial compound anisomycin (
54; reviewed in reference
30) (Fig. ) inhibits translation by binding to 60S ribosomal subunits and blocking peptide bond formation, thereby preventing elongation and causing polysome stabilization (
2,
30). More recently, the compound has been widely used as an extremely potent activator of kinase cascades in mammalian cells, especially the stress-activated mitogen-activated protein (MAP) kinase subtypes (
8,
9,
11,
18,
20,
24,
25,
42,
45,
52,
61). Kyriakis et al. (
34), studying a cycloheximide-activated kinase (p54 MAP kinase), identified a family of stress-activated protein kinases (SAPKs) encoded by three genes, each of whose transcripts may be alternatively processed. This subtype, which is more strongly activated by anisomycin, was independently identified as a UV radiation-activated kinase that binds to and phosphorylates the N terminus of c-Jun (c-Jun NH
2-terminal kinase [JNK] [
22,
28]). More recently, we showed, using in-gel kinase assays, that anisomycin strongly activates two kinases, p45 and p55, which we identified as MAP kinase-activated protein (MAPKAP) kinase 2 (MAPKAP K-2) (
10). This finding implied that anisomycin must also activate its upstream kinases, and we subsequently showed that it potently activates the MKK6→p38/RK→MAPKAP K-2 cascade in these cells (
25). Thus, anisomycin strongly activates two MAP kinase subtypes associated with the stress response. However, it is important to note that anisomycin equally strongly activates a third kinase, p70/85 S6 kinase (p70/85
S6k), which phosphorylates ribosomal protein S6 (
31). This response is sensitive to inhibition with rapamycin (
31), indicating that it is mediated through the FRAP/TOR kinase (
4,
5). Although we have shown that UV radiation also strongly stimulates S6 phosphorylation (
9), p70/85
S6k is not generally regarded as a stress kinase, whereas JNK/SAPKs and p38/RK are; all three are strongly activated by both UV radiation and anisomycin. As a result of its potent activation of MAP kinase subtypes which phosphorylate transcription factors such as c-Jun, ATF-2, and ternary complex factor in C3H 10T½ cells, anisomycin strongly induces transcription of several immediate-early (IE) genes (references
7,
9,
23,
25, and
26 and references therein).
The signalling and IE gene-inducing properties of anisomycin were originally thought to be secondary effects of translational arrest, arising either from loss of labile repressive proteins (reference
55 and references therein) or from the stress of translational arrest (
34). However, the fact that anisomycin-stimulated signalling and gene induction responses are clearly demonstrable at concentrations below those required for inhibiting translation (subinhibitory concentrations [
23,
39]), and conversely, that not all translational inhibitors activate signalling responses, invalidates this view. Puromycin and emetine have negligible signalling and gene-inducing effects, and although cycloheximide has some ability to activate these signalling responses, it is very much weaker than that of anisomycin, whereas it blocks translation equally well (
23,
26a). These studies conclusively dissociate translational arrest from signalling and gene induction, but they do not exclude the possibility that anisomycin-induced signalling requires its interaction with ribosomes (see Discussion and references
29 and
39). Furthermore, it remains possible that the compound exerts unknown chemical toxicity in these cells, which may explain its ability to activate stress kinases and thereby the IE genes.
In this study, we examined whether anisomycin is capable of eliciting homologous desensitization, a characteristic of several true signalling agonists. Many signalling mechanisms undergo a transient refractory period wherein they do not respond to restimulation with the same agent (reviewed in reference
16). This phenomenon, called homologous desensitization, is caused by degradation of a receptor or signalling enzyme (
16) or by negative-feedback mechanisms operating within signalling pathways (
6) (see Discussion). In addition, other stimuli which utilize the same desensitized component(s) will also not elicit a response (heterologous desensitization), whereas agents which act either through distinct pathways or downstream of the desensitized component(s) continue to elicit normal responses (reviewed in reference
16). We have studied the desensitization of a panel of five IE genes to diverse agents and found that anisomycin elicits virtually complete homologous desensitization of all these genes. Further, we show that this desensitization arises because anisomycin loses its ability to activate the JNK/SAPK and p38/RK kinases in desensitized cells. Among several agents tested, only UV- and hyperosmolarity-induced kinase activation was compromised in anisomycin-pretreated cells. These studies show that anisomycin acts like a true signalling agonist in eliciting highly specific homologous desensitization and further that the anisomycin-desensitized component(s) is not required for the activation of JNK/SAPKs or p38/RK by growth factors or tumor necrosis factor alpha (TNF-α), whereas it may play a significant role in UV- and hyperosmolarity-induced activation of these kinases.